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Summary p53 messenger RNA expression was examined using a cDNA probe in 76 fresh primary breast
tumour specimens, 15 of which came from patients treated with taxoxifen prior to surgery. A 2.8 kb mRNA
for p53 was expressed in 43 of the 76 specimens. In 19 tumours the levels were similar to those seen in
non-malignant (reduction mammoplasty) breast tissue, but in 24 tumours over-expression of mRNA for p53,
approaching that seen in three breast cancer cell lines, was found. The cell lines MCF-7, T47D and
MDA-MB-231 expressed three p53 mRNA species of about 2.8 kb and a fourth of 1.6 kb. Increased mRNA
expression for p53 correlated (P <0.05) with loss of genetic material from the short arm ofchromosome 17 as
demonstrated by allele loss with the VNTR probe YNZ 22.1. There was also statistically significant correlation
between increased p53 mRNA expression and low oestrogen receptor protein content in the tumours
(P <0.05), but not with other clinical parameters. The findings support the view that p53 is involved in breast
tumour biology, and suggest that its role may be complex.
p53 is a 53 kDa phosphoprotein with a short half-life
(5-45 min) (Reich & Levine, 1984; Halevy et al., 1988). The
role of p53 protein remains obscure although the p53 gene
has the structural features of a 'housekeeping' gene, including
absence of a TATA box (Reynolds et al., 1984; Bienz-
Tadmor et al., 1985). p53 may modulate transcriptional
activation by binding to DNA in a similar way to the myc
protein (Donner et al., 1982), allowing cells to progress from
a growth arrested state to an actively dividing state or to
bypass the need for platelet derived growth factor in the
induction of competence (Oren, 1986).
Despite persuasive evidence for its role as an oncogene
(Eliyahu et al., 1984, 1985; Parada et al., 1984; Editorial,
1988; Oren, 1986) there is also reason to believe that p53 can
act as a tumour suppressor gene (Green, 1989; Wang et al.,
1989). This paradox may be resolved if rearrangements of the
p53 DNA alter the structure, expression (Masuda et al.,
1987) or stability (Jenkins et al., 1985) of the 53 kDa protein
product and if the function of a mutated p53 product differs
from that of the normal gene (Green, 1989). The p53 gene
maps to the 13.1 region of the short arm of chromosome 17
(Miller et al., 1986). One previous study (Masuda et al.,
1987) did not find detectable changes in the p53 gene in
breast cancer. However, using the YNZ 22.1 probe
(Nakamura et al., 1988), which also maps near the tip of 17p
at 13.3, Mackay et al. (1988) found most patients had two
alleles in their constitutional (blood) DNA and 61% of these
informative patients had demonstrable loss of one allele (loss
of heterozygosity) in the tumour DNA.
p53 mRNA and p53 protein levels may (Reich et al., 1983)
or may not (Richon et al., 1989) correspond, since regulation
of p53 expression can occur at the level of mRNA abundance
or of p53 protein stability, depending on the system under
study (Rovinski et al., 1987).
While previous work on human breast cancer has
examined p53 protein expression (Cattoretti et al., 1988) or
chromosome 17p allelic loss (Mackay et al., 1988; Devilee et
al., 1989), no previous study has attempted to link the two by
relating expression of p53 mRNA to clinical parameters and/
or to deletions of chromosome 17p in breast cancer.
Materials and methods
Seventy-six patients with fully documented history, examina-
tion, staging investigations and follow-up, who presented with
breast cancer to the University Department of Surgery Breast
Unit at Longmore Hospital, Edinburgh, were studied. They
comprised 61 untreated and 15 tamoxifen-treated consecutive
breast cancer patients from whom sufficient material was
available for analysis. Tumour tissues (minimum 0.2 g) from
patients who underwent wedge biopsy, local excision or
mastectomy for carcinoma of the breast were frozen in liquid
nitrogen and stored at - 70°C. Tissue immediately adjacent
to that stored was fixed for histopathology and a further
piece of tumour submitted for oestrogen receptor assay. For
comparison with constitutional DNA, 20 ml of venous blood
was withdrawn for DNA extraction from white blood cells.
Breast tissue from 10 patients who underwent cosmetic
reduction mammoplasty and who did not have a personal or
family history of breast cancer was also obtained fresh and
immediately frozen.
The breast cancer cell lines MCF-7 (Soule et al., 1973),
MDA-MB-231 (Cailleau et al., 1974) and T-47D (Keydar et
al., 1979) were cultured and maintained under mycoplasma-
free (Barile, 1973) standard conditions. They were harvested
in the logarithmic phase of growth and the RNA was ex-
tracted for comparison with that from the tumours.
Ribonucleic acid extraction
From frozen tumour, total ribonucleic acid (RNA) was ex-
tracted using a modification of the method of Auffrey and
Rougeon (1980). Briefly, a known weight of frozen tumour
or a known number of cells washed in phosphate buffered
saline was pulverised and then disrupted in
2 ml 100 mg-' 3 M lithium chloride, 6 M urea and pre-
cipitated at 4° C overnight. The DNA was sheared using a
Soniprep 150 ultrasonic disintegrator (MSE Scientific
Instruments, Crawley, UK) with an ice jacket, the RNA was
recovered by centrifugation at 12,000 r.p.m. and the pellet
was taken up in 6 ml of 10 mM Tris buffer pH 7.0, 0.1%
sodium dodecyl sulphate (SDS). Three hundred jig of pro-
teinase K (Boehringer Mannheim, FRG) was added and the
sample was incubated at 37°C for 20 min. Protein was ex-
tracted using phenol equilibrated with Tris (0.1 M, pH 7) and
chloroform:isoamylalcohol (24: 1).
Following ethanol precipitation of the aqueous phase at
- 20°C, the RNA was recovered by centrifugation and dis-
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solved in autoclaved distilled water treated with diethyl
pyrocarbonate (DEPC, Sigma, USA) and stored in aliquots
at - 7OC. The quantity and purity of the RNA was assessed
by spectrophotometry at 260 nm and 240 nm.
Throughout the RNA extraction procedures, sterile dis-
posable plastic ware was used where possible; all solutions
were made up with autoclaved DEPC-treated water using
baked glassware and gloves were worn to minimise
exogenous ribonuclease contamination (Maniatis et al.,
1982).
Electrophoresis and transfer ofRNA
Twenty gig of total RNA was denatured with formamide and
formaldehyde at 55'C for 20 min; 2 gl loading buffer (50%
glycerol, I mM EDTA 0.4% bromophenol blue, 0.4% xylene
cyanol) and I gil 10gg ul-' ethidium bromide were added to
each sample. The denatured specimens were loaded on to a
1.1% agarose gel containing 0.66 M formaldehyde,
submerged beneath MOPS buffer (morpholinopropanesul-
phonic acid 0.2 M, pH 7.0, 50 mM sodium acetate pH 7.0,
5 mM EDTA) and the RNA species were separated electro-
phoretically (method modified from Fourney et al., 1988).
The gel was washed in two changes of 10 x standard saline-
citrate (I x SSC contains 150 mm sodium chloride, 300 mM
sodium citrate, I mM EDTA, pH 7.4) and photographed
under a UV transilluminator. The RNA was transferred to a
nylon filter (hybond-N, Amersham, UK) by capillary action
using 10 x SSC over 8 h (method modified from Southern,
1975). The filter was rinsed in 2 x SSC and air-dried, and the
RNA was covalently fixed to the membrane using a UV
transilluminator. The filter and remaining gel were photo-
graphed to check for adequate transfer of the RNA.
ethanol in the presence of salt (Steel, 1984). Precipitated
DNA was spooled from the alcohol, air-dried and redissolved
in Tris/EDTA buffer, and the concentration and purity of the
DNA were assessed using spectrophotometry at 260 nm and
280 nm. DNA was extracted from 20 ml venous blood in a
similar way, but with an additional protein extraction and
precipitation step prior to RNase treatment.
DNA (5gg) from each patient's blood and tumour was
digested using a bacterial endonuclease (for example, Tab I),
the samples were separated electrophoretically alongside
digested lambda markers on a 0.8% agarose gel, the DNA
fragments transferred to a hybond-N membrane (Amersham,
UK) using the Southern blot technique (Southern, 1975) and
the DNA was fixed to the membrane with ultraviolet light
and baking at 80°C for 2 h.
The membrane was incubated in hybridisation buffer (5 x
Denhart's, 5 x SSC, 0.1% SDS, 10% dextran sulphate) to
which Io1 c.p.m. ml-I' 32P-CTP-labelled YNZ 22.1 insert was
added (Nakamura et al., 1988) and allowed to hybridise for
24h.
Excess probe was washed from the membrane using suc-
cessive washes of 0.1% SDS and I x SSC and the DNA
fragments were detected by autoradiography at - 70°C to
pre-flashed Kodak XAR film.
Oestrogen receptors
The oestrogen receptor content was measured using the
Enzyme Immunoassay (EIA; kit from Abbott Laboratories,
North Chicago, IL, USA) and expressed in fmol per mg
protein for both the tumours and the cell lines. Oestrogen
receptor protein concentrations of 20 fmol mg-' protein or
greater were considered to be 'significant' (moderate to rich).
Probe hybridisation
Filters were pre-hybridised in 7% SDS, 0.5 M disodium hy-
drogen phosphate (pH 7.2) and I mM EDTA pH 7.0 (method
modified from Church & Gilbert, 1984) for 30 min at 65°C.
To this was added 32P-cytidine triphosphate (CTP) labelled
cDNA probe, with specific activity to io1 c.p.m. ml-' using a
random prime DNA-labelling system (Boehringer Mannheim,
FRG). 12P-CTP incorporated probe was separated from unin-
corporated radionucleotide using a Sephadex column (Nick
column, Pharmacia, UK) and denatured before addition to
the hybridisation solution.
To detect the p53 mRNA, the 2.1 kb cDNA clone
php53Bam of p53 protein mRNA cut from pBR322 (Zakut-
Houri et al., 1985) was used. Following 24 h hybridisation,
filters were washed to remove non-specifically attached probe
in two changes of 0.1% SDS 10mM disodium hydrogen
phosphate wash buffer at 65°C with agitation. The filters
were blotted dry, wrapped in clingfilm and exposed to pre-
flashed Kodak XAR film at - 70°C for up to 14 days.
The extent of hybridisation of radiolabelled probe to the
mRNA species was determined from densitometry (using a
laser densitometer constructed by the Medical Research
Council Human Genetics Unit) and expressed with respect to
hybridisation to the actin probe. The size of each mRNA
species was calculated from the position of ribosomal RNA
markers.
The filters were stripped of residual probe by washing at
80'C for 60 min in 0.1% SDS and the filter was checked by
autoradiography. As a standard probe, the Pst I insert
cDNA of plasmid 91, detecting mouse a-actin mRNA-
specific sequences (Minty et al., 1981) was then hybridised
and washed under the above conditions to quantify
accurately the mRNA in each total RNA sample loaded.
DNA extraction
DNA was extracted from frozen tissue by disrupting finely
chopped tissue in lysis buffer containing 1% SDS. Impurities
were removed by using RNase and proteinase K, then phenol
and chloroform, and the DNA was precipitated using
Results
A 2.8 kb p53 mRNA was detected in 43 of the 76 tumour
specimens (57%), in all three breast cancer cell lines and in
six of the 10 reduction mammoplasty specimens (Figure 1).
Low levels of this p53 mRNA (comparable to those found in
the six positive mammoplasty specimens) were also detected
in normal human tonsil, uterus and ovarian tissue (data not
shown). There were quantitative differences between the
tumour specimens and qualitative differences between the
tumours and the cell lines. Thirty-three of the 76 patients had
no detectable p53 mRNA in their tumour tissue and 19
patients had detectable p53 mRNA of 2.8 kb similar to quan-
tity to the reduction mammoplasty specimens that gave a
positive signal. Twenty-four patients had increased levels of
the 2.8 kb p53 mRNA approaching those found in the cell
lines.
Cell line Carcinoma Reduction
MCF7 MDA T47D 0 + ++ +++ Mammoplasty
I -28s
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Figure 1 p53 mRNA expression in three breast cancer cell lines
(MCF-7, MDA-MB-231 and T-47D), four representative breast
tumours with no mRNA expression (0), normal mRNA expres-
sion (+) comparable to control (reduction mammoplasty) tissue
and increased mRNA expression (+ + or + + +). In each case,
upper part of plate shows p53 mRNA species and lower part of
plate the control actin mRNA.76 A.M. THOMPSON et al.
The three breast cancer cell lines each yielded four p53
mRNA species. Three closely related species were of approxi-
mately 2.8 kb, with differences between cell lines in the
amounts of mRNA for each of these species. A fourth
(1.6 kb) p53 mRNA was strongly expressed in all three lines.
There was a significant tendency for increased tumour p53
mRNA expression to be associated with clinically
insignificant levels of oestrogen receptor protein (P = 0.049,
x2 test; Table I). No statistically significant correlation was
found between p53 mRNA expression and tumour size,
spread of the tumour to lymph nodes, histolopathological
features of the tumour, patient age or menopausal status.
The 76 patients all yielded sufficient DNA for analysis
from both venous blood and tumour. Using the phpS3Bam
cDNA probe for p53, polymorphic bands were detected in
less than 10% of samples with BamHI, Bgl II, Sca I, Ban II,
HinIll, EcoRI or Taq I and no rearrangements were
identified. However, with the YNZ 22.1 cDNA probe and
Taq I digests, 52 of the 76 (69%) blood DNA samples were
polymorphic and the remaining 24 were not informative.
Among the 53 informative patients there was unequivocal
loss of heterozygosity (loss or marked diminution in intensity
of one allele) in 30 tumours (58%) when compared to the
constitutive (blood) DNA (Figure 2).
Loss of genetic material from the tip of the short arm of
chromosome 17, as determined by loss of heterozygosity
using the YNZ 22.1 probe, was significantly correlated with
increased p53 mRNA expression (Table II, P = 0.04, x2 test).
Allelic loss was also correlated with low levels of oestrogen
receptor protein (P = 0.024, Fisher's exact test). When the
present data are combined with those from our earlier series
(Mackay et al., 1988) the association becomes highly
significant (Table III, P <0.01).
Table I p53 mRNA expression compared to oestrogen receptor
protein in 76 breast cancer specimens (X2 6.04, P = 0.049)
Oestrogen receptor p53 mRNA expression
(fmolmg-' protein) Nil Normal Increased
Significant 20 14 9
(>20)
Insignificant 13 5 15
(<20)
B T B T
Figure 2 Detection of DNA alleles using cDNA probe YNZ
22.1 following digestion of blood (B) tumour (T) DNA pairs with
the endonuclease Taql, demonstrating no allelic loss (left pair)
and loss of heterozygosity (right pair) from tumour DNA.
Table II p53 mRNA expression compared to allelic loss in 52
informative patients as demonstrated using the YNZ 22.1 probe for
the short arm of chromosome 17 (X2 6.29, P = 0.04)
p53 mRNA expression
Nil Normal Increased
Allele loss 10 6 14 (30)
No allele loss 12 7 3 (22)
Table III Allelic loss in 52 informative patients with the YNZ 22.1
probe compared to oestrogen receptor protein (P = 0.024, Fisher's
exact test)
Oestrogen receptor
(fmolmg-' protein)
Significant Insignificant
>20 <20
Allele loss 11 19
(19) (32)
No allele loss 15 7
(24) (11)
Figures in parentheses include 34 informative patients from our
previously reported data (Mackay et al., 1988; P = 0.004, Fisher's
exact test).
Discussion
This study has examined p53 mRNA expression and loss of
genetic material from the short arm of chromosome 17 in 76
patients. A 2.8 kb mRNA for p53 was detected in 43 of the
76 breast cancer specimens. This corresponds to the mRNA
for p53 identified in previous studies of human tissue (Har-
low et al., 1985; Baker et al., 1989). The quantitative
difference between tumours in p53 mRNA expression raises
the possibility that the p53 gene may fulfil different functions
in the patients with no detectable mRNA by comparison
with those in whom there was normal or increased expres-
sion. In those tumours where no p53 mRNA was detected,
this may reflect deficiency of normal (unmutated) p53 and
hence a reduced tumour suppressor function. Deletion of one
copy of the p53 gene is compatible with increased function of
the other (abnormal) gene. Thus, where there is normal or
increased p53 mRNA expression, this may be of a mutated
form (for example a point mutation), which therefore acts as
an oncogene, promoting carcinogenesis. Alternatively, loss of
one allele may confer a minor growth advantage, with subse-
quent mutation of the remaining p53 required to initiate or
promote carcinogenesis. If mutation were to occur first, loss
of the normal allele may be required to allow effective ex-
pression of the mutant p53, by analogy with co-transfection
studies of normal and mutated H-ras (Spandidos & Wilkie,
1988). The step between normal and mutated p53 cannot
readily be established using the Northern blot technique,
although future use of the polymerase chain reaction (Saiki
et al., 1985) should clarify the situation.
The qualitative differences between the tumours and cell
lines may reflect reading frame differences (likely to give rise
to the 1.6 kb mRNA) or splicing, or even different
adenylated tail lengths resulting in the three messages of
about 2.8 kb in size. However, when MCF-7 cells are grown
as xenografts in immunosuppressed mice, only a single 2.8 kb
p53 mRNA species and no 1.6 kb mRNA is detected in the
tumour tissue. This finding is independent of the rate of
tumour growth (A.M. Thompson, manuscript in prepara-
tion). A single p53 mRNA species of 1.8 kb has been noted
previously in NIH3T3 cells (Reich et al., 1983; Reich &
Levine, 1984) and this mRNA may correspond to the nuclear
mRNA regulating translation detected by Khochbin and
Lawrence (1988).
The three cell lines examined are distinguishable on
karyotype and on molecular analysis (using cDNA probes),
and they have different phenotypic characteristics; for ex-
ample, the MCF-7 line used in these studies has on average
120fmolmg-' total protein oestrogen receptor protein, T-
47D 40 fmol and MDA-MB-231 0 fmol. These lines also
show differing sensitivity to oestrogens and anti-oestrogens.
The consistently high level of p53 mRNA expressed in all
three lines thus implies that, in this in vitro setting, p53
mRNA expression is independent of oestrogen receptor pro-
tein content of the cells and of hormone sensitivity. Although
we have not confirmed the correlation noted in vivo between
increased p53 mRNA expression and oestrogen poor
tumours, this may be due to a myriad of factors includingp53 mRNA and 17p LOSS IN BREAST CANCER 77
the divergence of cell lines from the original tumour with
time.
Cattoretti et al. (1988), using an antibody PAbl8O0 specific
for human p53 protein in breast cancer specimens, noted a
correlation between oestrogen receptor negative tumours and
elevated p53 protein expression (P <0.05). Using this
antibody, no other significant correlation was identified.
These results therefore agree with our findings in relation to
p53 mRNA.
This study confirms that the loss of one YNZ 22.1 allele
from the short arm ofchromosome 17 occurs in over half the
breast tumours studied (Mackay et al., 1988, Devilee et al.,
1989) and establishes for the first time that this allele loss
correlates with clinically insignificant levels of oestrogen
receptor protein. The tip of the short arm of chromosome 17
is thus of importance in breast as well as in colon cancer
(Lothe et al., 1988; Vogelstein et al., 1989).
Although of all the highly informative probes available for
this study, YNZ 22.1, located at 17p 13.3, was the closest to
the p53 (17p 13.1) locus, it is still several megabases telomeric
to the p53 gene. The correlation between loss of
heterozygosity for YNZ 22.1 and p53 mRNA expression
provides evidence that there may be some link between a
putative gene conferring increased susceptibility to cancer
(Mackay et al., 1988) and the oncogene or tumour suppres-
sor gene function of p53.
Eleven of the 76 patients had tumours showing loss of
heterozygosity for YNZ 22.1, increased expression of p53
mRNA and low levels of oestrogen receptor protein. With
just 12 months mean follow-up, two of these patients have
already relapsed with metastatic disease. Continued follow-up
of the whole cohort will establish the prognostic significance
of the present findings.
The observation that, in almost a third of tumours, p53
mRNA levels were elevated while, in a comparable propor-
tion, the message was not detectable, supports the view that
p53 is involved in breast tumour biology. Whether this is as
an oncogene or as a tumour suppressor gene (possibly as
either, depending on the individual tumour) remains to be
seen. The advent of highly polymorphic probes for the p53
gene and the application of more recent technology, such as
the polymerase chain reaction, should resolve these issues.
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